KY-102

N/A

Report date: 2026/04/22 20:01:10

Base Information

Drug NameKY-102
Drug Alias NameKY102
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-Glypican-3
TargetsGlypican-3
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHangzhou Kunyu Biopharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHangzhou Kunyu Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A